ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1931

NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis
Abstract Number: 0584

Non-Clinical Evaluations of Deucravacitinib and Janus Kinase Inhibitor Specificity in Inflammatory or Homeostatic Pathways
Abstract Number: 2205

Non-Invasive in Vivo Metabolic Profiling of Inflammation in Joints and Entheses by Optoacoustic Imaging
Abstract Number: 0043

Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity
Abstract Number: 2033

Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology
Abstract Number: 1632

Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B
Abstract Number: 0207

Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
Abstract Number: 1732

Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Abstract Number: 0151

Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study
Abstract Number: 1888

Novel Small Molecule Modulator of the gp130 Receptor Shows Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis
Abstract Number: 2176

Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
Abstract Number: 0251

Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis
Abstract Number: 1024

Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance
Abstract Number: 1340

Nutrition-Related Behaviors and Beliefs – A Survey of Rheumatic Disease Patients
Abstract Number: 1187

Obesity Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters by Obesity Status in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].